Risici forbundet med øgede doser af myelosuppressive lægemidler Behandling med filgrastim alene forhindrer ikke trombocytopeni og anæmi fremkaldt af myelosuppresive behandlinger.
Risk associated with increased doses of myelosuppressive medicinal products Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive treatments.